Agence France-Presse

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...
Seeking Alpha

Compass Pathways accelerates potential COMP360 launch timeline by 9–12 months with NDA submission plans in Q3 2026

CEO Kabir Nath highlighted "the potential 9- to 12-month acceleration of our launch plans that we announced today" as a key update, citing the completion of enrollment for the COMP006 Phase III trial ...
Morningstar

Compass Pathways to Participate in Four Investor Conferences in September

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in ...
Hosted on MSN

Compass Pathways Earnings Call Highlights Progress and Plans

Compass Pathways Plc ((CMPS)) has held its Q3 earnings call. Read on for the main highlights of the call. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, ...
Agence France-Presse

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

U.S FDA has accepted IND application for COMP360 in PTSD, enabling the initiation of a Phase 2b/3 (COMP202) clinical trial in patients living with PTSD.